RBC Upgrades IGM Biosciences to Outperform From Sector Perform, Boosts Price Target to $21 From $9; Speculative Risk Kept
RBC Upgrades IGM Biosciences to Outperform From Sector Perform, Boosts Price Target to $21 From $9; Speculative Risk Kept
加拿大皇家銀行將IGM Biosciences從行業表現上調至跑贏大盤，將目標股價從9美元上調至21美元；投機風險保持不變
Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.
登入免費觀看全文
登入/註冊